Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic…
$TGTX TG Therapeutics 3Q Operating Income Beats Estimates (Bloomberg) -- TG Therapeutics reported operating income for the third quarter that beat the average analyst estimate. THIRD QUARTER RESULTS Operating income $85.9 million vs. $29.4 million y/y, estimate $73.9 million
$TGTX ... TGTX TG Therapeutics misses by $0.02, beats on revs (59.82) Q3 Earnings Results EPS: $0.35 vs. $0.37 consensus | MISS by $0.02 Revenue: $259.9 mln vs. $245.5 mln consensus | BEAT by 5.9% Revenue Growth: +60.8% yr/yr. GUIDANCE For full year 2026, the company reaffirmed…
@chucktrade $TGTX .. I trimmed the stock... and added some November 20 calls at $70... Although, I am not that optimistic.
Focus for the week – $ABNB $BILL $CAH $CHYM $CROX $ELF $EW $FROG $GPN $KOD $LIVN $LLY $MRNA $PCTY $REGN $SDGR $SG $SN $SOXS $SPOT $TGTX* $THC $TOST $TREE $U $VLTO $VSXY $XMTR
Key Economic News & Earnings – Week of November 9, 2026 Economic Data • Tuesday, Nov 10 (BTO): CPI • Thursday, Nov 12 (BTO): Initial Claims, Continuing Claims • Friday, Nov 13 (BTO): PPI Earnings Monday, Nov 9 • BTO: $CEG, $MNDY, $TGTX Tuesday, Nov 10 • ATC: $CRWV,
$TGTX pulled back to test the 60 level and the 59.30 pivot of a 15-week long base. https://t.co/FsVMoUNyxb
8 analysts rate TGTX Buy on consensus.
Consensus price target: $69.71 (+16.52% upside from $59.83)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Echelard Yann director | Nov 24, 2025 | Sale | 5,000 | $162.85K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $616.29M | +87.32% | $447.18M |
| 2024 | $329M | +40.8% | $23.38M |
| 2023 | $233.66M | +8290.02% | $12.67M |
Stock data for TGTX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics